

Please type a plus sign (+) inside this box ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheet as necessary)


Complete if Known

Application Number	10/763,558
Confirmation Number	
Filing Date	January 23, 2004
First Named Inventor	John E. Nash et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	K1008/20454
Customer Number	03000

Sheet 1 of 5

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
W		1,902,418		Pilgrim	03/1933
		2,398,544		Lockart	04/1946
		2,737,946		Hein, Jr.	03/1956
		2,762,370		Venditty	09/1956
		2,800,903		Smoot	07/1957
		3,815,594		Doherty	06/1974
		3,887,699		Yolles	06/1974
		3,930,505		Wallach	01/1976
		4,165,739		Doherty et al.	08/1979
		4,315,742		Nash et al.	02/1982
		4,406,656		Hattler et al.	09/1983
		4,589,412		Kensey	05/1986
		4,631,052		Kensey	12/1986
		4,637,905		Gardner	01/1987
		4,652,441		Okada et al.	03/1987
		4,658,817		Hardy	04/1987
		4,664,112		Kensey et al.	05/1987
		4,679,558		Kensey et al.	07/1987
		4,686,982		Nash	08/1987
		4,690,672		Veltrup	09/1987
		4,700,705		Kensey et al.	10/1987
		4,747,406		Nash	05/1988
		4,747,821		Kensey et al.	05/1988
		4,749,376		Kensey et al.	06/1988
		4,790,813		Kensey	12/1988
		4,795,438		Kensey et al.	12/1988
		4,839,215		Starling et al.	06/1989
		4,900,303		Lemelson	02/1990
		4,994,033		Shockey et al.	02/1991
		5,021,044		Sharkawy	06/1991





Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheet as necessary)				Complete if Known	
				Application Number	10/763,558
				Confirmation Number	
				Filing Date	January 23, 2004
				First Named Inventor	John E. Nash et al.
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	K1008/20454
Customer Number	03000				
Sheet	2	of	5		

U.S. PATENT DOCUMENTS

W	5,037,432	Molinari	08/1991
	5,042,984	Kensey et al.	08/1991
	5,087,244	Wolinsky et al.	02/1992
	5,112,305	Barath et al.	05/1992
	5,199,951	Spears	04/1993
	5,244,460	Unger et al	09/1993
	5,279,565	Klein et al.	01/1994
	5,288,502	McGinity et al.	02/1994
	5,415,636	Forman	05/1995
	5,415,637	Khosravi	05/1995
	5,456,667	Ham et al.	10/1995
	5,496,267	Drasler et al.	03/1996
	5,498,238	Shapland et al.	03/1996
	5,527,292	Adams et al.	06/1996
	5,591,159	Taheri	01/1997
	5,607,421	Jeevanandam et al.	03/1997
	5,655,548	Nelson et al.	08/1997
	5,674,197	van Muiden et al.	10/1997
	5,704,911	Parsons	01/1998
	5,718,921	Mathiowitz et al.	02/1998
	5,755,682	Knudson et al.	05/1998
	5,836,905	Lemelson et al.	11/1998
	5,810,836	Hussein et al.	08/1998
	5,840,059	March et al.	11/1998
	5,871,469	Eggers et al.	02/1999
	5,878,751	Hussein et al.	03/1999
	5,879,713	Roth et al.	03/1999
	5,893,840	Hull et al.	04/1999
	5,904,670	Schreiner	05/1999
	5,912,017	Mathiowitz et al.	06/1999
W	5,925,016	Chornenky et al.	07/1999



Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheet as necessary)				Complete If Known	
				Application Number	10/763,558
				Confirmation Number	
				Filing Date	January 23, 2004
				First Named Inventor	John E. Nash et al.
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	K1008/20454
Customer Number	03000				
Sheet	3	of	5		

U.S. PATENT DOCUMENTS

W		5,935,119		Guy et al.	08/1999
I		5,941,868		Kaplan et al.	08/1999
I		5,997,525		March et al.	12/1999
I		6,080,170		Nash et al.	06/2000
W		6,261,585		Sefton et al.	07/2001

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T
		Office	Number	Kind Code (If known)			
W		EP	0 807 412	A1	United States Surgical Corporation	11/19/97	
I		EP	0 876 803	A2	C.R. Bard, Inc.	11/11/98	
I		EP	0 876 803	A3	C.R. Bard, Inc.	11/11/98	
I		DE	296 19 029	U1	Kietke, Georg	11/02/96	
I		WO	97/32551		Energy Life Systems Corporation	09/12/97	
I		WO	98/19614		Fogarty, Thomas	05/14/98	
I		WO	98/39038		Scimed Life Systems, Inc.	09/11/98	
I		WO	98/49964		C.R. Bard, Inc.	11/12/98	
I		WO	99/22655		Scimed Life Systems, Inc.	05/14/99	
I		WO	99/22658		Scimed Life Systems, Inc.	05/14/99	
I		WO	99/27985		Scimed Life Systems, Inc.	06/10/99	
I		WO	99/33510		Hydrocision, Inc.	07/08/99	
I		WO	99/44523		Scimed Life Systems, Inc.	09/10/99	
W		WO	99/44524		Scimed Life Systems, Inc.	09/10/99	

OTHER NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
W		Arras et al., The Delivery of Angiogenic Factors to the Heart by Microsphere Therapy, Nature Biotechnology, Volume 16, 159-162, February 1998;	
I		Bonan, Raul, M.D., Local Drug Delivery for the Treatment of Thrombus and Restenosis, The Journal of Invasive Cardiology, 8:399-408, October 1996;	
I		Edelman, et al., Basic Fibroblast Growth Factor Enhances The Coupling Of Intimal Hyperplasia And Proliferation Of Vasa Vasorum In Injured Rat Arteries, J. Chin Invest, Volume 89, February 1992, 465-473;	
W		Edelman et al., Perivascular and Intravenous Administration Of Basic Fibroblast Growth Factor: Vascular And Solid Organ Deposition, Proc. Natl. Acad. Sci., USA, Vol. 90, 1513-1517, February 1993;	



Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheet as necessary)				Application Number	10/763,558
				Confirmation Number	
				Filing Date	January 23, 2004
				First Named Inventor	John E. Nash et al.
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	K1008/20454
Customer Number	03000				
Sheet	4	of	5		
U.S. PATENT DOCUMENTS					

W		Fasol et al., Experimental Use Of A Modified Fibrin Glue To Induce Site-Directed Angiogenesis From The Aorta To the Heart, The Journal of Thoracic and Cardiovascular Surgery, Volume 107, 1432-1439, June 1994;	
		Goldman et al., Experimental Method For Producing A Collateral Circulation To The Heart Directly From The Left Ventricle, The Journal of Thoracic and Cardiovascular Surgery, 31:364-374, March, 1965;	
		Harada, et al., Basic Fibroblast Growth Factor Improves Myocardial Function In Chronically Ischemic Porcine Hearts, J. Chin. Invest, Volume 94, August 1994, 623-630;	
		Kimura et al., Cellular Response In Subretinal Neovascularization Induced by bFGF-Impregnated Microspheres, IOVS, February, 1999, Vol. 40, 524-528;	
		Krabbash et al., Histological Findings After Transmyocardial Laser Revascularization, The Journal of Cardiac Surgery, 11:326-331, 1996;	
		Lopez, et al., Basic Fibroblast Growth Factor in a Porcine Model of Chronic Myocardial Ischemia: A comparison of Angiographic, Echocardiographic and Coronary Flow Parameters. The Journal of Pharmacology and Experimental Therapeutics, Vol. 282, No. 1, pgs. 385-390, 1997;	
		Mack et al., Biologic Bypass with the Use of Adenovirus-Mediated Gene Transfer of the Complementary Deoxyribonucleic Acid for Vascular Endothelial Growth Factor 121 Improves Myocardial Perfusion and Function in the Ischemic Porcine Heart, The Journal of Thoracic and Cardiovascular Surgery, 115:168-177, January 1998;	
		Massimo et al., Myocardial Revascularization By A New Method Of Carrying Blood Directly From The Left Ventricular Cavity Into The Coronary Circulation, J. Thorac, Surg., 34:257-264, August, 1957;	
		Mirhoseini, et al., New Concepts in Revascularization of the Myocardium, Ann. Tho. Surg., 45:415-420, April 1988;	
		Moosdorf, et al., Transmyocardial Laser Revascularization-Morphologic Pathophysiologic and Historical Principles of Indirect Revascularization of The Heart Muscle, Z Kardiol, 86(3): 147-164, March, 1997;	
		Nishi et al., Basic Fibroblast Growth Factor Impregnated Hydrogel Microspheres For Embolization of Cerebral Arteriovenous Malformations, ASAIO Journal, 1998, M405-M410;	
		Pelletier, et al., Angiogenesis and Growth Factor Expression in a Model of Transmyocardial Revascularization, Annals of Thoracic Surgery, 66:12-18, 1998;	
		Pifarre, et al., Myocardial Revascularization by Transmyocardial Acupuncture, A Physiologic Impossibility, The Journal of Thoracic and Cardiovascular Surgery, 58:424-431, September 1969;	
W		Sanborn, et al., Abstract of Percutaneous Endocardial Gene Therapy In Vivo Gene Transfer and Expression, The Journal of the American College of Cardiology, 33:262A, February 1999;	



Please type a plus sign (+) inside this box →

PTO/SB/O&A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheet as necessary)				Complete if Known	
				Application Number	10/763,558
				Confirmation Number	
				Filing Date	January 23, 2004
				First Named Inventor	John E. Nash et al.
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	K1008/20454
Customer Number	03000				
Sheet	5	of	5		
U.S. PATENT DOCUMENTS					

		Sellke et al., Basic FGF Enhances Endothelium-Dependent Relaxation of the Collateral Perfused Coronary Microcirculation. The American Physiological Society, 1994, pgs. H1303-H1311;	
		Sellke et al., Therapeutic Angiogenesis With Basic Fibroblast Growth Factor: Technique and Early Results, Ann Thorac, Surg., 1540-1544, 1998;	
		Sen et al., Transmyocardial Acupuncture: A New Approach to Myocardial Revascularization, Journal of Thoracic and Cardiovascular Surgery, 50:181-187, August, 1965;	
		Tabata et al., In Vitro Sorption and Desorption of Basic Fibroblast Growth Factor From Biodegradable Hydrogels, Biomaterials 19 (1998) 1781-1789;	
		Taguchi et al., Preparation of a Novel Functional Hydrogel Consisting Of Sulfated Glucoside-bearing Polymer: Activation Of Basic Fibroblast Growth Factor, 386-391;	
		Uchida et al., Angiogenic Therapy of Acute Myocardial Infarction by Intrapericardial Injection of Basic Growth Factor and Heparin Sulfate: An Experimental Study, the American Heart Journal, 130:1182-1188, December 1995;	
		Wilensky et al., Direct Intraarterial Wall Injection Of Microparticles Via A Catheter: A Potential Drug Delivery Strategy Following Angioplasty, American Heart Journal, Volume 122, 1136-1140, October 1991;	
		Wintzer et al., Transmyocardial Laser Revascularization. Historical Features in Human Nonresponder Myocardium appearing in Circulation, 95(c): 371-375, January 21, 1997.	
EXAMINER 		DATE CONSIDERED 2/6/06	
<small>*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>			